Company Profiles

driven by the PitchBook Platform

MSI Methylation Sciences

Description

Developer of small molecule therapy for adjunctive treatment of major depressive disorder. The company's lead product Strada for treatment of major depressive disorder is based upon Ademetionin, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle.

2007

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$30M

Latest Deal Amount

$49.7M

Total Amount Raised

Description

Developer of small molecule therapy for adjunctive treatment of major depressive disorder. The company's lead product Strada for treatment of major depressive disorder is based upon Ademetionin, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle.

Website:

www.methylationsciences.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery
Pharmaceuticals

Primary Office

108-4475 Wayburne Drive Burnaby, British Columbia V5G 4X4Canada +1 (604) 435-5155
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore MSI Methylation Sciences's full profile, request a free trial.

    MSI Methylation Sciences Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    MSI Methylation Sciences Investors (4)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    BC Advantage FundsVenture CapitalMinority000 0000000 0000
    GrowthWorksVenture CapitalMinority000 0000000 0000
    Inventages Venture CapitalVenture CapitalMinority000 0000000 0000
    Quark VentureVenture CapitalMinority000 0000000 0000
    BC Advantage Funds Venture Capital
    GrowthWorks Venture Capital
    Inventages Venture Capital Venture Capital
    Quark Venture Venture Capital

    MSI Methylation Sciences Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Allan FieldsPresident
    David MacDonald Ph.DVice President, Product Development & Chief Technology Officer
    Nancy HarrisonCo-Founder, President & Chief Business Officer
    Beth CameronVice President, Clinical Research
    Steven Targum MDChief Medical Officer
    Allan Fields President
    David MacDonald Ph.D Vice President, Product Development & Chief Technology Officer
    Nancy Harrison Co-Founder, President & Chief Business Officer
    Beth Cameron Vice President, Clinical Research
    Steven Targum MD Chief Medical Officer

    MSI Methylation Sciences Board Members (9)

    NameRepresentingRoleSinceContact
    Info
    Allan FieldsMSI Methylation SciencesPresident000 0000
    Axel Bouchon Ph.DSelfBoard Member000 0000
    Barry GuldMSI Methylation SciencesCo-Founder & Board Member000 0000
    Graham JacksonSelfBoard Member000 0000
    Gunnar Weikert Ph.DInventages Venture CapitalFounder, Chairman & Chief Executive Officer000 0000
    Allan Fields President MSI Methylation Sciences
    Axel Bouchon Ph.D Board Member Self
    Barry Guld Co-Founder & Board Member MSI Methylation Sciences
    Graham Jackson Board Member Self
    Gunnar Weikert Ph.D Founder, Chairman & Chief Executive Officer Inventages Venture Capital
    Request full access to PitchBook